Open AccessMedicine

M. Omata, A. Cheng, N. Kokudo, M. Kudo, J. Lee, J. Jia, R. Tateishi, K. Han, Y. K. Chawla, S. Shiina, W. Jafri, D. Payawal, Takamasa Ohki, S. Ogasawara, Pei‐Jer Chen, C. Lesmana, L. Lesmana, R. Gani, S. Obi, A. Dokmeci, S. Sarin

2017.6.15Hepatology International

DOI: 10.1007/s12072-017-9799-9

tlooto Summary

The latest guidelines for the treatment of HCC recommend evidence-based management and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.

Abstract

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.

Citation format

OMATA, M., et al. Asia–pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatology International, 2017, 11: 317–370.